Ivo Kocák

Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial

Johann S. de Bono, Stéphane Oudard, Mustafa Özgüroğlu et al. · The Lancet · 2010 · 3.3K citations

Urology, Medicine, Pharmacology +7

Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial

Noel W. Clarke, Paweł Wiechno, B. Yа. Alekseev et al. · The Lancet Oncology · 2018 · 405 citations · Full text

Urology, Oncology, Genitourinary Cancer +5

Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial

Michele Maio, Karl D. Lewis, Lev Demidov et al. · The Lancet Oncology · 2018 · 210 citations · Full text

Medicine, Melanoma, Immunology +10

A phase I/II study of siltuximab (CNTO 328), an anti-interleukin-6 monoclonal antibody, in metastatic renal cell cancer

JF Rossi, Sylvie Négrier, Nicholas D. James et al. · British Journal of Cancer · 2010 · 184 citations · Full text

Impact of cabazitaxel on 2-year survival and palliation of tumour-related pain in men with metastatic castration-resistant prostate cancer treated in the TROPIC trial

Amit Bahl, Stéphane Oudard, Bertrand Tombal et al. · Annals of Oncology · 2013 · 170 citations · Full text